Novavax submits application to Health Canada for updated protein-based 2024-2025 formula COVID-19 vaccine

Novavax

2 July 2024 - Novavax's filing is aligned with NACI, US. FDA, EMA and WHO recommendations on vaccine composition.

Novavax announced that it has filed for authorisation with Health Canada for its 2024-2025 Formula COVID-19 vaccine (NVX-CoV2705) for individuals aged 12 and older.

Read Novavax press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Canada , Vaccine , Dossier , COVID-19